Type I Interferons Suppress Anti-parasitic Immunity and Can Be Targeted to Improve Treatment of Visceral Leishmaniasis
Rajiv Kumar, Patrick T. Bunn, Siddharth Singh, Susanna S. Ng, Marcela Montes de, Fabian de Labastida Rivera, Shashi Bhushan Chauhan, Neetu Singh, Rebecca J. Faleiro, Chelsea L. Edwards, Teija Frame, Meru Sheel, Rebecca Austin, Steven Lane, Tobias Bald, Mark J. Smyth, Geoffrey R. Hill, Shannon E. Best, Ashraful Haque, Dillon Corvino, Nicola Waddell, Lambross T. Koufariotis, Pamela Mukhopadhay, Madhukar Rai, Jaya Chakravarty, Om Prakash Singh, David L. Sacks, Susanne Nylén, Jude E. Uzonna, Shyam Sundar, Christian Engwerda
Abstract
T cell responses in mice and humans. Thus, manipulation of type I IFN signaling is a promising strategy for improving disease outcome in VL patients.
Topics & Concepts
Visceral leishmaniasisLeishmania donovaniImmune systemImmunologyImmunityLeishmaniaBiologyLeishmaniasisInterferonParasitic diseaseParasite hostingDiseaseMedicineInternal medicineComputer scienceWorld Wide WebResearch on Leishmaniasis StudiesEosinophilic Disorders and SyndromesTrypanosoma species research and implications